Motor System II: Basal Ganglia

  • Stanley Jacobson
  • Elliott M. Marcus
  • Stanley Pugsley


The term “basal ganglia” originally included the deep telencephalic nuclei: the caudate, putamen, globus pallidus, claustrum, and nucleus accumbens. The globus pallidus and putamen are lens shaped and are called lenticular nuclei. Collectively the putamen and caudate are called the corpus striatum. Additional structures now included within this group are the substantia nigra, the subthalamic nuclei, the ventral tegmental area, and the ventral pallidum. One is very familiar with disease of the basal ganglia due to the widespread presence of Parkinson’s disease with its tremor at rest.


Caudate Putamen Globus pallidus Subthalamic nucleus 


  1. Albin D, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366–75.PubMedCrossRefGoogle Scholar
  2. Cooper IS. Involuntary movement disorders. New York: Hoeber Medical Division; 1969a.Google Scholar
  3. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. New York: Oxford University Press. (see in particular chapter 10: dopamine); 1991. p. 285–337.Google Scholar
  4. Denny-Brown D. The basal ganglia and their relation to disorder of movement. London: Oxford University Press; 1962.Google Scholar
  5. Galvez-Jimenez N, editor. Movement disorders. Semin Neurol. 2001;21:1–123.Google Scholar
  6. Hallett M. Classification and treatment of tremor. JAMA. 1991;266:1115–7.PubMedCrossRefGoogle Scholar
  7. Haymaker W, Mehler WF, Schiller F. Extrapyramidal motor disorders. In: Haymaker W, editor. Bing’s local diagnosis in neurological disease. St Louis: CVMosby; 1969. p. 404–40.Google Scholar
  8. Hurtig HI, Stern MB, editors. Movement disorders. Neurol Clin. 2001;19:523–788.Google Scholar
  9. Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore-Munich: Urban & Schwarzenberg; 1988. 499 ppGoogle Scholar
  10. Lowe J, Lennox G, Leigh PN. Disorders of movement and system degenerations. In: Graham DI, Lantos PL, editors. Greenfield’s neuropathology, vol. 2. London: Arnold; 1997. p. 281–366.Google Scholar
  11. Marsden CD, Fahn S, editors. Movement disorders II. London/Boston: Butterworths; 1987. 468 ppGoogle Scholar
  12. Noback CR, Strominger NL, Demarest RJ. Chapter 24: The human nervous system; introduction and review. 4th ed. Philadelphia: Lea & Febiger; 1991. p. 375–95.Google Scholar
  13. Oppenheimer DR. Diseases of the basal ganglia, cerebellum and motor neurons. In: Adams JH, Corsellis JAN, Dicker LW, editors. Greenfield’s neuropathology. Edward Arnold: London; 1984. p. 700–47.Google Scholar
  14. Quinn N. Fortnightly review: Parkinson’s disease: recognition and differential diagnosis. BMJ. 1995;310:447–52.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Rascol O, Lees AJ, editors. Dyskinesias movement disorders. 1999;14 Suppl 1:1–80.Google Scholar
  16. Riley DE, Lang AE. Movement disorders. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. Boston: Butterworth Heinemann II; 2000. p. 1889–930.Google Scholar

Specific References and Citations Parkinson Disease

  1. Agid Y, Cervera D, Hirsh E, et al. Biochemistry of Parkinson’s disease 28 years later: a critical review. Mov Disord. 1989;4(S1):126–44.CrossRefGoogle Scholar
  2. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S, editors. Movement disorders II. London/Boston: Butterworths; 1987. p. 166–230.Google Scholar
  3. Albin RI, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl D-aspartate receptors in Presymptomatic Huntington’s disease. N Engl J Med. 1990;322:1293–8.PubMedCrossRefGoogle Scholar
  4. Alexander GE, De Long MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci. 1986;9:375–81.CrossRefGoogle Scholar
  5. Alyward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in pre-symptomatic and symptomatic stages of Huntington’s disease. Mov Disord. 2000;15:552–60.CrossRefGoogle Scholar
  6. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the Subthalamic nucleus for the alleviation of l-methyl-4 phenyl 1,2,3,6, Tetrahydropyridine (MPTP) induced parkinsonism in the primate. Mov Disord. 1991;6:288–92.PubMedCrossRefGoogle Scholar
  7. Ballard PH, Tetrud JW, Langston JW. Permanent human parkinsonism due to l-methyl-4 phenyl, 1,2,3,6, tetra-Hydropyrine (mptp): seven cases. Neurology. 1985;35:949–56.PubMedCrossRefGoogle Scholar
  8. Bandmann O, Sweeney MG, Daniel SE, et al. Multiple system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. Brain. 1997;49:1598–604.Google Scholar
  9. Berciano J. Olivopontocerebellar atrophy. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Urban & Schwartzenberg: Baltimore/Munich; 1988. p. 131–51.Google Scholar
  10. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the Subthalamic nucleus. Science. 1990;249:1436–8.PubMedCrossRefGoogle Scholar
  11. Bhatia KP. Familial (idiopathic) paroxysmal dyskinesias: an update. Semin Neurol. 2001;21:69–74.PubMedCrossRefGoogle Scholar
  12. Bhatia KP, Griggs RC, Ptacek LJ. Episodic movement disorders as channelopathies. Mov Disord. 2000;15:429–3.CrossRefGoogle Scholar
  13. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol. 2001;21:85–90.PubMedCrossRefGoogle Scholar
  14. Brooks DJ. Detection of preclinical Parkinson's disease with PET. Neurology. 1991;41(Suppl 2):24–7.PubMedCrossRefGoogle Scholar
  15. Cooper IS. Involuntary movement disorders. New York: Paul B Hoeber; 1969b.Google Scholar
  16. Cote L, Crutcher MD. The basal ganglia. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 3rd ed. New York: Elsevier; 1991. p. 647–59.Google Scholar
  17. Cotzias GC, Papavasiliou PS, Gellen R. Modification of parkinsonism – chronic treatment with L-Dopa. N Engl J Med. 1969;280:337–45.PubMedCrossRefGoogle Scholar
  18. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374–9.PubMedCrossRefGoogle Scholar
  19. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie Levodopa or dopamine agonist induced dyskinesia in Parkinson's disease: Implications for the future strategies in treatment. Mov Disord. 1990;5:100–8.PubMedCrossRefGoogle Scholar
  20. Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. Chorea and myoclonus in the monkey induced by gamma amino butyric acid antagonism in the lentiform complex the site of drug action and a hypothesis for the neural mechanism of chorea. Brain. 1988;121:1–33.Google Scholar
  21. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain. 1995;118:759–70.PubMedCrossRefGoogle Scholar
  22. De Bie RMA, Schuurman PR, de Haan PS, et al. Unilateral pallidotomy in advanced Parkinson’s disease: a retrospective study of 26 patients. Mov Disord. 1999;14:951–7.PubMedCrossRefGoogle Scholar
  23. Delwaide PJ, Gance M. Pathophysiology of parkinson’s signs. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore/Munich: Urban and Schwarzenberg; 1988. p. 59–73.Google Scholar
  24. Deuschl G. Treatment options for tremor. N Engl J Med. 2000;342:505–7.PubMedCrossRefGoogle Scholar
  25. Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature. 1999;399(6738 Suppl):A32–9.PubMedCrossRefGoogle Scholar
  26. Duvoisin RC. Familial Parkinson’s disease. Neurosci News. 1998;1:43–6.Google Scholar
  27. Ebersbach G, Sojer M, Valladeoriopla F, et al. Comparative analysis of gait in Parkinson’s disease cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain. 1999;122:1349–55.PubMedCrossRefGoogle Scholar
  28. Eidelberg D, Sortel A, Joachim C, et al. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology a discrete clinical pathological entity. Brain. 1987;110:993–1013.PubMedCrossRefGoogle Scholar
  29. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain. 1990;113:1823–4.PubMedCrossRefGoogle Scholar
  30. Forno LS, Alford EC. Pathology of Parkinson’s disease. In: Roller WC, editor. Handbook of Parkinson’s disease. Marcel-Dekker: NY; 1987. p. 209–36.Google Scholar
  31. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344:710–9. (see also editorial by Fischbach GD, Mc Khann GM. Cell therapy for Parkinson’s disease. Engl J Med. 2001;344:763–5PubMedCrossRefGoogle Scholar
  32. Furukawa Y, Kish SJ. Dopa responsive dystonia: recent advances and remaining issues to be addressed. Mov Disord. 1999;14:709–15.PubMedCrossRefGoogle Scholar
  33. Gerfan CR, Engbar TM. Molecular neuroanatomic mechanisms of Parkinson’s disease. Neurol Clin. 1992;10:435–49.Google Scholar
  34. Gibb WRG. The neuropathology of Parkinsonian disorders. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore/Munich: Urban & Schwarzenberg; 1988. p. 205–23.Google Scholar
  35. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain. 1989;112:1171–92.PubMedCrossRefGoogle Scholar
  36. Goerdert M, Jakes R, Spillantini MG. Alpha-Synuclein and the Lewy body. Neurosci News. 1998;1:47–51.Google Scholar
  37. Goetz CG. Charcot on Parkinson's disease. Mov Disord. 1986;1:27–32.PubMedCrossRefGoogle Scholar
  38. Goldblatt D, Markesbery W, Reeves AG. Recurrent Hemichorea following striatal lesions. Arch Neurol. 1974;31:51–4.PubMedCrossRefGoogle Scholar
  39. Graybiel AM, Ragsdale CW. Histochemically distinct compartments in stratum of human, monkey and cat demonstrated by Acetylthiocholinesterase staining. Proc Natl Acad Sci U S A. 1978;75:5723–6.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Growdon JH, Hirsh MJ, Wurtman RJ, Wiener W. Oral choline administration to patients with tardive dyskinesia. N Engl J Med. 1977;297:524–7.PubMedCrossRefGoogle Scholar
  41. Guridi J, Obesco JA. The subthalamic nucleus, hemiballismus and Parkinson’s disease: reappraisal of a neurosurgical dogma. Brain. 2001;124:5–19.PubMedCrossRefGoogle Scholar
  42. Gusella JF, Wexler NS, Conneally DM, et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nature. 1983;306:234–8.PubMedCrossRefGoogle Scholar
  43. Guttman M. Dopamine receptors in Parkinson’s disease. Neurol Clin. 1992;10:377–86.PubMedGoogle Scholar
  44. Hallett M, Litvan I, et al. Scientific position paper of the movement disorder society evaluation of surgery for Parkinson’s disease. Mov Disord. 2000;15:436–8.PubMedCrossRefGoogle Scholar
  45. Hornykiewicz OD. Physiological, biochemical and pathological backgrounds of Levao-Dopa and possibilities for the future. Neurology. 1970;20:1. (Part 2), 1–13PubMedCrossRefGoogle Scholar
  46. Hornykiewicz O, Kish S, Beckler LE, et al. Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med. 1986;315:347–531.PubMedCrossRefGoogle Scholar
  47. Huntington G. On chorea. Med Surg Report. 1872;26:317–21.Google Scholar
  48. Huw RM, Lees AJ, Wood NW. Neurofibrillary tangles Parkinsonian disorders-tau pathology and Taugenetics. Mov Disord. 1999;14:731–6.CrossRefGoogle Scholar
  49. Jankovic J. Parkinsonism plus syndromes. Mov Disord. 1989a;4(Suppl l):S95–119.PubMedCrossRefGoogle Scholar
  50. Jancovic J. Tourette’s syndrome. N Engl J Med. 2001;345:1184–92.CrossRefGoogle Scholar
  51. Jankovic J, Fahn S. The phenomenology of tics. Mov Disord. 1986;1:17–26.PubMedCrossRefGoogle Scholar
  52. Jankovic J, Fahn S. Dystonic syndromes. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore/Munich: Urban & Schwarzenberg; 1988. p. 283–314.Google Scholar
  53. Jarman PR, Davis MB, Hodgson SV, et al. Paroxysmal dystonic choreoathetosis: genetic linkage studies in a British family. Brain. 1997;120:2125–30.PubMedCrossRefGoogle Scholar
  54. Jarman PR, Bhatia KP, Davie C, et al. Paroxysmal dystonic choreoathetosis: clinical features and investigation of pathophysiology in a large family. Mov Disord. 2000;15:648–57.PubMedCrossRefGoogle Scholar
  55. Kandel E. Disorders of thought: schizophrenia. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 3rd ed. New York: Elsevier; 1991. p. 853–68.Google Scholar
  56. Keenen RE. The Eaton collaborative study of Levo Dopa therapy in parkinsonism. Neurology. 1970;20(Part 2):46–59.CrossRefGoogle Scholar
  57. Kertesz A. Corticobasal degeneration. J Neurol Neurosurg Psychiatry. 2000;68:275–6.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Kertesz A, Martinez-Lage P, Davidson W, Munoz DG. The Corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 2000;55:1368–75.PubMedCrossRefGoogle Scholar
  59. Klawans HL, Moses H, Nausieda DA, et al. Treatment and prognosis of Hemiballismus. N Engl J Med. 1976;295:1348–50.PubMedCrossRefGoogle Scholar
  60. Klawans HL, Paulson GW, Ringel SP, Barbeau A. Use of L-Dopa in the detection of Presymptomatic Huntington's chorea. N Engl J Med. 1972;286:1332–4.PubMedCrossRefGoogle Scholar
  61. Klawans HL. The pathophysiology of drug-induced movement disorders. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Urban and Schwarzenberg: Baltimore/Munich; 1988. p. 315–26.Google Scholar
  62. Koller WC, editor. Role of the controlled release formulation of Carbidopa-Levodopa in the treatment of Parkinson’s disease. Neurology. 1992a;42(Suppl 1):Sl–60.Google Scholar
  63. Koller WC. Initiating treatment of Parkinson's disease. Neurology. 1992b;42(Suppl 1):29–32.Google Scholar
  64. Kopin IJ. MPTP toxicity: Implications for research in Parkinson’s disease. Ann Rev Neurosci. 1988;11:81–96.PubMedCrossRefGoogle Scholar
  65. Lamousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 1998;339:1105–11.CrossRefGoogle Scholar
  66. Lang AE, Lozano AM. Medical progress: Parkinson’s disease. N Engl J Med. 1998;339:1044–53. 11301143PubMedCrossRefGoogle Scholar
  67. Lang AE, Lozano AM, Duff ME, et al. Posteroventral medial pallidotomy in advanced Parkinson’s disease. N Engl J Med. 1997;337:1036–42.PubMedCrossRefGoogle Scholar
  68. Langston JW, Ballard P. Parkinsonism induced by 1-methyl, 4-phenyl-1,2,3,6, tetrahydropyridine (MPTP): Implications for treatment and pathogenesis of Parkinson’s disease. Can J Neurol Sci. 1984;11:160–5.PubMedCrossRefGoogle Scholar
  69. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of Meperidine – analog synthesis. Science. 1983;219:979–80.PubMedCrossRefGoogle Scholar
  70. Langston JW, Widner H, Goetz CG, et al. Case assessment program for intracerebral transplantation (CAPIT). Mov Disord. 1992;7:2–13.PubMedCrossRefGoogle Scholar
  71. Laplane D, Levasseur M, Pillone B, et al. Obsessive compulsive and other behavioral changes with bilateral basal ganglia lesions. Brain. 1989;112:699–725.PubMedCrossRefGoogle Scholar
  72. Lees AJ, Tolosa E. Tics. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore/Munich: Urban and Schwarzenberg; 1988. p. 275–81.Google Scholar
  73. Lees AJ. The Steele-Richardson, Olszewski syndrome (progressive Supranuclear palsy). In: Marsden CD, Fahn S, editors. Movement Disorders II. London/Boston: Butterworths; 1987. p. 272–87.Google Scholar
  74. Lewin R. Trail of ironies to Parkinson's disease. Science. 1983;224:1083–5.CrossRefGoogle Scholar
  75. Lewin R. Brain enzyme is the target of drug toxin. Science. 1984;225:1460–2.PubMedCrossRefGoogle Scholar
  76. Le Witt DA. Clinical studies with and pharmacokinetic considerations of sustained release Levodopa. Neurology. 1992;42(Suppl 1):29–31.Google Scholar
  77. Lieberman A. Emerging perspectives in Parkinson’s disease. Neurology. 1992;42(Suppl 4):5–7.PubMedGoogle Scholar
  78. Lindvall O. Cerebral implantation in movement disorders: state of the art. Mov Disord. 1999;14:201–5.PubMedCrossRefGoogle Scholar
  79. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247:514–77.CrossRefGoogle Scholar
  80. Litwin I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol. 2001;21:41–8.CrossRefGoogle Scholar
  81. Litwin I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele- Richardson- Olszewski syndrome) from related disorders? A clinicopathological study. Brain. 1997;120:25–9.Google Scholar
  82. Martin JB, Gusella JF. Huntington's disease: pathogenesis and management. N Engl J Med. 1986;315:1267–76.PubMedCrossRefGoogle Scholar
  83. Mathuranath PS, Xuereb JH, Bak T, Hodges JR. Corticobasal degeneration and/or frontal temporal dementia? A report of two overlap cases and review of the literature. J Neurol Neurosurg Psychiatry. 2000;68:304–12.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;35:453–61.PubMedCrossRefGoogle Scholar
  85. Meissen GJ, Myers RH, Mastromauro CA, Koroshetz WJ, Klinger KW, Farrer LA, Watkins PA, Gusella JF, Bird ED, Martin JB. Predictive testing for Huntington's disease with use of a linked DNA marker. N Engl J Med. 1988;318(9):535–42.PubMedCrossRefGoogle Scholar
  86. Mena I, Court J, Fuenzalida S, et al. Chronic Manganeses poisoning: treatment with L-Dopa or 5-OH tryptophan. N Engl J Med. 1970;282:5–10.PubMedCrossRefGoogle Scholar
  87. Martin JR. Hemichorea (hemiballismus) without lesions in the corpus Luysii. Brain. 1951;80:1–10.CrossRefGoogle Scholar
  88. Meyers R, Sweeney DB, Swidde JT. Hemiballismus: etiology and surgical treatment. J Neurol Neurosurg Psychiatry. 1947;58:672–92.Google Scholar
  89. Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. The role of the subthalamic nucleus in experimental chorea evidence from 2-Desoxyglucose metabolic mapping and horse radish peroxidase tracing studies. Brain. 1989;112:1533–48.PubMedCrossRefGoogle Scholar
  90. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord. 1999;14:725–30.PubMedCrossRefGoogle Scholar
  91. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol. 1991;48:800–4.PubMedCrossRefGoogle Scholar
  92. Myers RH, Vonsattel JP, Stevens TJ, et al. Pathologic assessment of severity in Huntington’s disease. Neurology. 1988;38:341–7.PubMedCrossRefGoogle Scholar
  93. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 1999;22:123–44.PubMedCrossRefGoogle Scholar
  94. Papp MI, Lantos PL. The distribution of oligodendroglia inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994;117:235–43.PubMedCrossRefGoogle Scholar
  95. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely & Jones; 1817. Reprinted - the classics of neurology neurosurgery library, Birmingham, Gryphen editions, 1986Google Scholar
  96. Patten BM. Wilson’s disease. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore/Munich: Urban & Schwarzenberg; 1988. p. 179–90.Google Scholar
  97. Pauls DL, Leckman JF. The inheritance of Gilles de la Tourette's syndrome and associated behaviors: evidence for autosomal dominant transmission. N EngI J Med. 1986;315:993–7.CrossRefGoogle Scholar
  98. Pearce RKB. L- Dopa and dyskinesias in normal monkeys. Mov Disord. 1999;14(Suppl 1):9–12.PubMedGoogle Scholar
  99. Penney JB, Young AB. Huntington’s disease. In: Jankovic J, Tolosa E, editors. Parkinson’s disease. Baltimore: Urban and Schwarzenberg; 1988. p. 167–78.Google Scholar
  100. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration a clinical study of 36 cases. Brain. 1994;117:1183–96.PubMedCrossRefGoogle Scholar
  101. Roberts L. Huntington’s gene: so near and so far. Science. 1990;247:624–17.PubMedCrossRefGoogle Scholar
  102. Sarma K, Waltz JM, Riklan M, Koslow M, Cooper IS. Relief of intention tremor by thalamic surgery. J Neurol Neurosurg Psychiat. 1970;33:7–15.CrossRefGoogle Scholar
  103. Sax DS, Vonsattel JP. Chorea and progressive dementia in an 88-year-old woman. N Engl J Med. 1992;326:117–24.CrossRefGoogle Scholar
  104. Schmidt WR, Jarcho LW. Persistent dyskinesias following phenothiazide therapy. Arch Neurol. 1966;14:369–77.PubMedCrossRefGoogle Scholar
  105. Schneider JS, Pope A, Simpson K, et al. Recovery from experimental parkinsonism in primates with GM1 Ganglioside treatment. Science. 1992;256:843–6.PubMedCrossRefGoogle Scholar
  106. Scheinberg IH, Steinlieb I. Wilson’s disease. Philadelphia: W B Saunders; 1984.Google Scholar
  107. Schuurman PR, Bosch DA, Bossuyt PMM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med. 2000;342:461–8.PubMedCrossRefGoogle Scholar
  108. Schwarz GA, Barrows LJ. Hemiballism without involvement of Luy’s body. Arch Neurol. 1960;2:420–34.PubMedCrossRefGoogle Scholar
  109. Sethi KP. Movement disorders induced by dopamine blocking agents. Semin Neurol. 2001;21:59–68.PubMedCrossRefGoogle Scholar
  110. Siemers E, Reddy V. Profile of patients enrolled in a new movement disorders clinic. Mov Disord. 1991;6:336–41.PubMedCrossRefGoogle Scholar
  111. Singer HS. Current issues in Tourette’s syndrome. Mov Disord. 2000;15:1051–63.PubMedCrossRefGoogle Scholar
  112. Sladek JR, Redmond BE Jr, Collier TJ, et al. Transplantation advances in Parkinson’s disease. Mov Disord. 1989;4(Suppl 1):S120–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Stanley Jacobson
    • 1
  • Elliott M. Marcus
    • 2
  • Stanley Pugsley
    • 3
  1. 1.BostonUSA
  2. 2.Jamaica PlainUSA
  3. 3.South Abington Twp.USA

Personalised recommendations